Suppr超能文献

疟疾的分子疫苗

Molecular vaccines for malaria.

作者信息

Bruder Joseph T, Angov Evelina, Limbach Keith J, Richie Thomas L

机构信息

GenVec, Inc., Gaithersburg, MD, USA.

出版信息

Hum Vaccin. 2010 Jan;6(1):54-77. doi: 10.4161/hv.6.1.10463. Epub 2010 Jan 29.

Abstract

The basic premise of vaccination is the triggering of host immune responses leading to the induction of adaptive immunity having sufficient magnitude and duration to provide long term protection. This has been achieved by many licensed vaccines, the majority based on attenuated or inactivated organisms, although often the protective antigens and underlying molecular mechanisms have not been identified. However, this traditional approach has not led to the development of a licensed vaccine for malaria or for several other devastating infectious diseases. Recently, substantial efforts have been focused on applying rational molecular design principles toward the development of novel vaccines for these refractory pathogens. In this review, we discuss the molecular aspects of antigen design, adjuvant advancement and the development of vaccine delivery systems as they are being applied to malaria vaccines.

摘要

疫苗接种的基本前提是触发宿主免疫反应,从而诱导出具有足够强度和持续时间的适应性免疫,以提供长期保护。许多已获许可的疫苗都实现了这一点,其中大多数基于减毒或灭活生物体,尽管通常尚未确定保护性抗原和潜在的分子机制。然而,这种传统方法尚未导致开发出用于疟疾或其他几种毁灭性传染病的许可疫苗。最近,大量努力集中在将合理的分子设计原则应用于开发针对这些难治性病原体的新型疫苗。在这篇综述中,我们讨论了抗原设计、佐剂改进以及疫苗递送系统开发的分子方面,因为它们正被应用于疟疾疫苗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验